Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een proef om benralizumab te onderzoeken bij kinderen met eosinofiele ziekten (CLIPS)

27 oktober 2026 bijgewerkt door: AstraZeneca

Fase 3, open-label onderzoek om de veiligheid, farmacokinetiek en werkzaamheid van benralizumab bij kinderen met eosinofiele ziekten (CLIPS) te evalueren

The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

This study is open-label, multicentre, basket study to evaluate the safety, PK, pharmacodynamic (PD), efficacy, and immunogenicity of repeat dosing of benralizumab subcutaneous (SC) every 4 weeks (Q4W) in male and female children with rare eosinophilic diseases.

Paediatric participants with eosinophilic granulomatosis with polyangiitis (EGPA) will be enrolled in the first cohort.

Paediatric participants with hypereosinophilic syndrome (HES) will be enrolled in the second cohort. Additional cohorts in other eosinophilic diseases may be added in future protocol amendments.

The study consists of 3 periods:

  1. Screening period: 1 to 4 weeks
  2. Open-label treatment period: 52 weeks
  3. Open-label extension period: at least 52 weeks (plus safety follow-up [SFU] weeks after last investigational product [IP] administration)

All eligible participants will receive benralizumab SC Q4W during the 52-week open-label treatment period.

All participants who complete the 52-week open-label treatment period on IP will be offered the opportunity to continue into an extension period. The extension period is intended to allow each participant at least an additional one year of treatment with benralizumab.

Studietype

Ingrijpend

Inschrijving (Geschat)

14

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • São Paulo, Brazilië, 01232-010
        • Werving
        • Research Site
    • Ontario
      • Toronto, Ontario, Canada, M5G1X8
        • Werving
        • Research Site
      • Lille, Frankrijk, 59037
        • Werving
        • Research Site
      • Montpellier, Frankrijk, 34295
        • Geschorst
        • Research Site
      • Ahmedabad, Indië, 380052
        • Werving
        • Research Site
      • Petah Tikva, Israël, 49202
        • Werving
        • Research Site
      • Guadalajara, Mexico, 44620
        • Werving
        • Research Site
      • Rotterdam, Nederland, 3015 GD
        • Werving
        • Research Site
      • Kielce, Polen, 25-734
        • Werving
        • Research Site
      • Warsaw, Polen, 04-730
        • Nog niet aan het werven
        • Research Site
      • Altındağ, Turkije (Türkiye), 06230
        • Werving
        • Research Site
      • Istanbul, Turkije (Türkiye), 34093
        • Werving
        • Research Site
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80045
        • Werving
        • Research Site
    • Ohio
      • Cincinnati, Ohio, Verenigde Staten, 45229
        • Werving
        • Research Site
      • Highland Hills, Ohio, Verenigde Staten, 44106-2624
        • Werving
        • Research Site

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

6 jaar tot 17 jaar (Kind)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

All Cohorts:

  • Male or female participants must be aged 6 to < 18 years of age at the time of signing the assent form and their caregiver signing the informed consent form.
  • Body weight greater than (>=) 15 kilograms (kg).

EGPA Cohort:

  • Therapy with corticosteroids: The prescribed dose of oral corticosteroids (OCS) (greater than [>] 0.1 milligrams per kilogram per day (mg/kg/day), max dose of 50 milligrams per day (mg/day) must be stable (that is, no adjustment of the dose) for at least 4 weeks prior to baseline (Visit 2).
  • Immunosuppressive therapy: If receiving immunosuppressive therapy, the dosage must be stable for at least 4 weeks prior to baseline (Visit 2).

HES Cohort:

  • Documented HES diagnosis, defined as history of persistent eosinophilia >1500 cells/µL without secondary cause on 2 examinations ≥1 month apart and evidence of eosinophil-mediated organ involvement.
  • Symptomatic active HES, or history of a prior flare, or considered eligible based on disease severity per investigator judgement.
  • AEC ≥1000 cells/µL at screening (Visit 1).
  • Documented negative testing for Fip1-like 1 gene fused with the platelet-derived growth factor receptor alpha gene (FIP1L1-PDGFR) fusion tyrosine kinase gene translocation.

Exclusion Criteria:

All Cohorts:

  • Any current malignancy or history of malignancy.
  • History of anaphylaxis to any biologic therapy or vaccine.
  • Known, pre-existing, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological, respiratory, or any other system abnormalities.
  • Previous receipt of benralizumab in an interventional clinical study.

EGPA Cohort:

  • Diagnosed with granulomatosis with polyangiitis (previously known as Wegener'granulomatosis) or microscopic polyangiitis.
  • EGPA relapse: any deterioration in EGPA and/or organ-threatening EGPA that per Investigator judgement renders participants unstable in their EGPA within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2).
  • Life-threatening EGPA: imminently life-threatening EGPA disease within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2), as per Investigator judgement.

HES Cohort:

  • Life-threatening HES or HES complications, as judged by the investigator.
  • Hypereosinophilia of unknown significance (HE-US).
  • Diagnosis of systemic mastocytosis.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: EGPA/HES Cohort: Benralizumab

Participants with greater than or equal to (>=) 35 kg weight will receive benralizumab dose-1 and participants with less than (<) 35 kg weight will receive benralizumab dose-2 as SC injection Q4W during the 52-week treatment period. All participants who complete the 52-week treatment period will be offered the opportunity to continue into an extension period.

Benralizumab will be administered as SC injection on Q4W.

Andere namen:
  • FASENRA

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of Participants with Adverse Events (AEs)
Tijdsspanne: From screening (Week -4 to -1) until Week 52

The safety and tolerability of benralizumab will be evaluated.

From screening (Week -4 to -1) until Week 52
Serum Concentrations of Benralizumab
Tijdsspanne: Weeks 0, 12, 24, 25, 36, and 52

The PK of benralizumab will be evaluated.

Weeks 0, 12, 24, 25, 36, and 52

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
EGPA Cohort: Percentage of Participants with Remission at Week 24
Tijdsspanne: At Week 24

Remission defined as Paediatric Vasculitis Activity Score (PVAS) = 0 and oral corticosteroid (OCS) intake less than or equal to (<=) 0.1 mg/kg/day.

At Week 24
Number of Participants with Positive Antidrug Antibody (ADA)
Tijdsspanne: Weeks 0, 12, 24, 36, 48, and 52

The immunogenicity of benralizumab will be evaluated.

Weeks 0, 12, 24, 36, 48, and 52
Change From Baseline in Peripheral Blood Eosinophil Count
Tijdsspanne: From Baseline to Weeks 0, 12, 24, 36, 52

The PD effect of benralizumab on peripheral blood eosinophil count will be evaluated.

From Baseline to Weeks 0, 12, 24, 36, 52
EGPA Cohort: Time to First EGPA Relapse
Tijdsspanne: Up to 52 weeks

The efficacy of benralizumab on time to first relapse will be assessed. EGPA relapse will be defined as worsening or persistence of active disease since the last visit characterized by: a) Active vasculitis (PVAS > 0); OR b) Worsening of asthma symptoms (based on Asthma Control Questionnaire - Interviewer Administered [ACQ-IA]); OR c) Active nasal and/or sinus disease with worsening in at least one sino-nasal symptom question warranting any of the following: 1) Increase OCS; OR 2) Increase/addition of immunosuppressive medication; OR 3) Hospitalisation related to EGPA worsening.

Up to 52 weeks
HES Cohort: Time to first HES worsening/flare
Tijdsspanne: Up to 52 weeks

The effect of benralizumab on HES worsening/flares will be evaluated.

Up to 52 weeks
HES Cohort: Percentage of participants who experience a HES worsening/flare
Tijdsspanne: Up to 52 weeks

The effect of benralizumab on HES worsening/flares will be evaluated.

Up to 52 weeks
HES Cohort: Number of HES worsening/flares (annualised rate/year)
Tijdsspanne: Up to 52 weeks

The effect of benralizumab on HES worsening/flares will be evaluated. The annualised HES worsening/flare rate will be calculated as follows:

The total number of flares *365.25 / total duration of follow-up in the treatment period (days).

Up to 52 weeks
HES Cohort: Percentage of Participants requiring an increase in corticosteroid dose
Tijdsspanne: Up to 52 weeks

The effect of benralizumab on corticosteroid use will be evaluated.

Up to 52 weeks
HES Cohort: Time to first haematologic relapse
Tijdsspanne: Up to 52 weeks

The time to first haematologic relapse will be defined as the time from first dose of IP to the first post baseline visit with Absolute eosinophil count [AEC] ≥ 1000 cells/uL.

Up to 52 weeks
HES Cohort: Percentage of Participants with haematologic relapse
Tijdsspanne: Up to 52 weeks

The effect of benralizumab on haematologic measures of disease activity will be evaluated.

Up to 52 weeks
HES Cohort: Percentage of Participants who have AEC < 500 cells/μL for 24 weeks
Tijdsspanne: Up to 52 weeks

The effect of benralizumab on haematologic measures of disease activity will be evaluated.

Up to 52 weeks
HES Cohort: Patient Global Impression of Change (PGI-C) Score
Tijdsspanne: Weeks 12, 24, 36 and 48

The effect of benralizumab on participant/caregiver reported measures of disease severity and health status will be assessed. The PGI-C instrument captures the participant's overall evaluation of response to treatment, and rated on a 7-point PGI-C scale ranging from 1 ('much better') to 7 ('much worse').

Weeks 12, 24, 36 and 48

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

17 april 2025

Primaire voltooiing (Geschat)

20 februari 2028

Studie voltooiing (Geschat)

14 mei 2029

Studieregistratiedata

Eerst ingediend

17 juli 2024

Eerst ingediend dat voldeed aan de QC-criteria

17 juli 2024

Eerst geplaatst (Werkelijk)

22 juli 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

28 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

27 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • D3255C00004
  • 2023-508533-14-00 (Andere identificatie: EU CT)
  • EMEA-001214-PIP09-21-M02(EGPA) (Andere identificatie: Paediatric Investigational Plan Number)
  • EMEA-001214-PIP04-19-M02 (HES) (Andere identificatie: Paediatric Investigational Plan Number)
  • 2023 (Subsidie/contract van de Amerikaanse NIH)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via there quest portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

IPD-tijdsbestek voor delen

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-toegangscriteria voor delen

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .